Chiesi Group and Arbor Biotechnologies agreed an exclusive collaboration and license to develop Arbor’s lead in vivo gene‑editing candidate ABO‑101 and access Arbor’s editing platform, in a deal worth up to $2.1 billion. The partnership covers the ongoing Phase I/II redePHine trial (NCT06839235) in primary hyperoxaluria type 1 (PH1) and options on additional liver targets. Under the agreement, Chiesi will support development and global commercialization while Arbor supplies the Cas12i2 editing payload delivered in an Acuitas lipid nanoparticle (LNP). ABO‑101 is designed as a one‑time, liver‑directed HAO1 knockout to reduce oxalate production. The deal represents Chiesi’s first direct push into gene editing and gives Arbor a major global partner and funding runway. The transaction is notable for pairing an established rare‑disease biopharma with a next‑gen CRISPR platform and an LNP delivery strategy, signaling commercial confidence in liver‑directed in vivo editing approaches and accelerating clinical development and regulatory engagement.